The Wadas Laboratory’s focus is to combine novel ligand discovery techniques with innovative radiochemistry strategies to develop radiopharmaceutical solutions that can be implemented to detect and treat a variety of diseases including cancer, cardiovascular disease, arthritis and Alzheimer’s disease. In collaboration with academic and industrial partners, researchers in the Wadas Laboratory pioneered novel immuno-positron emission tomography strategies involving zirconium-89, were the first group to demonstrate that standard optical imaging techniques could be used to detect Cerenkov radiation in vivo to direct image-guided drug delivery and have contributed to the development of a targeted alpha-particle therapy for metastatic uveal melanoma that is now in clinical trials. The laboratory employs a dynamic group of researchers with expertise in chemistry, physics, antibody engineering and medicine. It thrives on collaboration and welcomes new collaborations! The laboratory’s academic collaborators include the University of California-Berkeley, Memorial Sloan Kettering Cancer Center, the Moffitt Cancer and Research Institute, Washington University School of Medicine, Wake Forest University Health Sciences and the Iowa State University. Industrial partners include Hoffmann La Roche, Inc.; Lumiphore, Inc.; Modulation Therapeutics, Inc.; Advanced Innovation Partners, Inc.; and Viewpoint Molecular Targeting, Inc.